GANX Gain Therapeutics Inc
1,378
$2.54
$0.14
(5.22%)
| Watchers | 1,378 |
| 52-Wk Low | $2.00 |
| 52-Wk High | $5.45 |
| Market Cap | $45.85M |
| Volume | 239,414.00 |
| 52-Wk High | $5.45 |
| 52-Wk Low | $2.00 |
Gain Therapeutics, Inc. (NASDAQ:GANX) Director Jeffrey Scott Riley Acquires 30,000 SharesTicker Report • about 1 month ago
Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) Director Jeffrey Scott Riley bought 30,000 shares of the business's stock in a transaction on Thursday, March 28th. The shares were acquired at...
Share to Feed
Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) saw a large increase in short interest during the month of March. As of March 15th, there was short interest totalling 156,700 shares, an...
Related Stocks: GANX...
Gain Therapeutics (GANX Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
BETHESDA, Md., April 01, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) ( Gain , or the Company ), a clinical-stage biotechnology company leading the discovery and development of...
BETHESDA, Md., March 26, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) ( Gain , or the Company ), a clinical-stage biotechnology company leading the discovery and development of...
Gain Therapeutics GAAP EPS of -$1.71 misses by $0.14, revenue of $0.05M misses by $0.25M...
Gain Therapeutics' Former CEO and current Board Member Eric Richman to participate in fireside chat hosted by Public Ventures President Lou Basenese and Aberdeen Investment Management President Jeb...